Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lead-in study for hemophilia A and B gene therapy trials
NCT03587116Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2018
- Primary completion
- Dec 2024
- Modality
- Replacement Enzymes
- Countries
- 18
01
Overview
Phase 3, open-label trial in hemophilia B (HB) and hemophilia A (2 cohorts), sponsored by Pfizer. Primary endpoint: Annualized Bleeding Rate for Treated Bleeds and All Bleeds. Started Jul 2018; status: completed.
02
Conditions
hemophilia B (HB)hemophilia A
Beyond the preview
Go deeper on NCT03587116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587116.